Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: The Inhaled Insulin Treatment Questionnaire (IITQ)

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Rubin, Richard R ^a   Peyrot, Mark ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; INSULIN; INSULIN ASPART; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; INHALED INSULIN TREATMENT QUESTIONNAIRE; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCORING SYSTEM; SHORT FORM 36; DIABETES MELLITUS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; INSTRUMENTATION; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; REPRODUCIBILITY; VALIDATION STUDY;

ADMINISTRATION, INHALATION; ADULT; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 77952252542     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-32     Document Type: Article

References (23)

1. Charpentier G, Fleury F, Dubroca I, Vaur L, Clerson P. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diab Metab 2005, 31:189-195.
2. Marra G, . DIAB. &TE.S Study Group How patients perceive diabetes and diabetes therapy. Acta Biomed 2004, 75:164-170. DIAB. &TE.S Study Group.
3. Kelley K, Dempsey C. An evaluation of an insulin transfer programme delivered in a group setting. J Clin Nurs 2007, 16:152-158. 10.1111/j.1365-2702.2007.01772.x, 17584424.
4. Tahrani AA, Digwood S, Lee C, Moulilk P. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract 2007, 61:329-335. 10.1111/j.1742-1241.2006.01190.x, 17263721.
5. Peyrot M, Rubin RR. Assessing health-related quality of life (HRQOL): The Insulin Delivery System Rating Questionnaire (IDSRQ). Diabetes Care 2005, 28:53-58. 10.2337/diacare.28.1.53, 15616233.
6. Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. The Diabetes Educator 2009, 35:136-146. 10.1177/0145721708326989, 19244569.
7. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2:113-127. 10.1046/j.1524-4733.1999.02210.x, 16674343.
8. Bradley C, . ed Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. 1994, Chur, Switzerland: Harwood Academic Publishers, ed.
9. Rave K, Heise T, Pfutzner A, Boss AH. Coverage of postprandial glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007, 30:2307-2308. 10.2337/dc07-0478, 17586744.
10. Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2005, 110:17-21.
11. Pfutzner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005, 2:1097-1106. 10.1517/17425247.2.6.1097, 16296812.
12. Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technology and Therapeutics 2010, 12:49-55. 10.1089/dia.2009.0115, 20082585.
13. Ware JH, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36). I: Conceptual framework and item selection. Medical Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
14. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004, 27:1318-1323. 10.2337/diacare.27.6.1318, 15161782.
15. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001, 24:1556-1559. 10.2337/diacare.24.9.1556, 11522698.
16. Peyrot M, Rubin RR. Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The Insulin Delivery System Rating Questionnaire. Diabetes Care 2005, 28:53-58. 10.2337/diacare.28.1.53, 15616233.
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1969, London, Academic Press.
18. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health and Quality of Life Outcomes 2007, 5:69-75. 10.1186/1477-7525-5-69, 2241589, 18096074.
19. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005, 28:2543-2545. 10.2337/diacare.28.10.2543, 16186296.
20. Mollema ED, Snoek FJ, Ader HJ, Heine RJ, Ploeg HM. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. Journal of Psychosomatic Research 2001, 51:665-672. 10.1016/S0022-3999(01)00229-X, 11728507.
21. Makine C, Karsidag C, Kadioglu P, Ilkova H, Karsidag K, Skovlund SE, Snoek FJ, Pouwer F. Symptoms of depression and diabetes-specific emotional distress are associated with negative appraisals of insulin therapy in insulin naïve patients with type 2 diabetes mellitus. A study from the European Depression in Diabetes (EDID) Research Consortium. Diabetic Medicine 2009, 26:28-33. 10.1111/j.1464-5491.2008.02606.x, 19125757.
22. Peyrot M, Rubin RR, Polonsky WH. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technology and Therapeutics 2008, 10:461-466. 10.1089/dia.2008.0031, 19049375.
23. Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 2009, 32:1411-1417. 10.2337/dc08-2256, 19470837.